ERBB3 is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 6 are open and 1 is closed. Of the trials that contain ERBB3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

ERBB3 is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain ERBB3 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

ERBB3 is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ERBB3 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 3 clinical trials for melanoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and melanoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 1 is open and 2 are closed. Of the trials that contain ERBB3 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain ERBB3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ERBB3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].